1. Home
  2. BAOS vs CLGN Comparison

BAOS vs CLGN Comparison

Compare BAOS & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baosheng Media Group Holdings

BAOS

Baosheng Media Group Holdings

BUY

Current Price

$0.17

Market Cap

5.7M

ML Signal

BUY

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

HOLD

Current Price

$3.55

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAOS
CLGN
Founded
2018
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Business Services
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.2M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
BAOS
CLGN
Price
$0.17
$3.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 239.8K
44.4K
Earning Date
11-27-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.26
52 Week High
$3.82
$4.78

Technical Indicators

Market Signals
Indicator
BAOS
CLGN
Relative Strength Index (RSI) 23.30 54.39
Support Level $0.16 $0.34
Resistance Level $0.26 $3.91
Average True Range (ATR) 0.02 0.39
MACD 0.01 -0.09
Stochastic Oscillator 8.24 39.17

Price Performance

Historical Comparison
BAOS
CLGN

About BAOS Baosheng Media Group Holdings

Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: